Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): a multi-arm phase I trial.
CONCLUSIONS: : SBRT delivered in 5 consecutive fractions up to the doses evaluated is well tolerated. The MTD was reached in four (a, b, c and f) of the seven study arms. Recruitment for (d), (e) and (g) arms is still ongoing.
ADVANCES IN KNOWLEDGE: : In a prospective dose-escalation trial, the MTD of 50 Gy/10 Gy fraction and 35 Gy/7 Gy fraction were defined for primary and metastatic lesions and as boost after prior RT dose ≤50 Gy, respectively.
PMID: 30325662 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Deodato F, Macchia G, Cilla S, Ianiro A, Sallustio G, Cammelli S, Buwenge M, Mattiucci GC, Valentini V, Morganti AG Tags: Br J Radiol Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Radiology | Study | Toxicology | UK Health